iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Sun Pharma: M&A focus on Specialty and Ems

21 Mar 2024 , 05:48 PM

Analysts of IIFL Securities hosted Sun Pharma at IIFL’s Investor Conference in Mumbai. Sun to focus on Specialty & Complex generics and will continue to evaluate potential acquisitions along with in-licensing deals to further strengthen US Specialty portfolio. The company is particularly looking at Derma and Ophthal assets in the Speciality business. Given the high cost of developing biosimilars and fairly high price erosion, mgmt has prioritised Specialty over Biosimilars and will enter the market once the company has bio-manufacturing capacities. Sun’s focus will remain on prescription led growth in India and expect it to be in-line or above IPM growth going ahead. Analysts of IIFL Securities believe Sun will continue to do well on the back of growth momentum sustaining in Speciality business, reducing dependency on US generics and double-digit growth in India business. 

Focus on prescription led growth in India: 

Over the years, volume growth and new launches have accounted for three-fourths of Sun’s India business vs two-thirds for IPM. Sun’s focus will remain on prescription led growth in India and expect it to be in-line or above IPM growth going ahead. Part of the 20% MR addition is to increase penetration in tier 2/3 markets. Although, Sun has some exposure towards trade generics which came as a part of Ranbaxy acquisition but trade generics has become a smaller piece of the business given mgmt’s focus on branded generics in India. 

Will continue to invest in Specialty business and EMs through potential M&As: 

Sun’s focus has shifted to specialty and complex generics and the incremental filings has been towards complex portfolio. Sun is particularly looking for specialty assets in Derma and Ophthal. The upcoming triggers for Specialty is the PDUFA date for Deuruxo in Jul’24 and EU filing for Nidlegy in 1HCY24. Ilumya’s psoriatic arthritis recruitment has picked up in non-eastern EU markets and US, which should lead to higher R&D spends going ahead. Mgmt expects gradual recovery at Mohali plant (QoQ sales in 3Q has been flat) and is yet to invite USFDA for inspection. 

Sun to prioritise Specialty over Biosimilars, given Sun doesn’t have internal manufacturing capacities and will be looking to acquire biologics manufacturing capacities. The double whammy in the biosimilar market is the high cost of development per biosimilar which is around USD80-100m per product along with fairly high price erosion of biosimilars with a prime example of bHumira where innovator is protecting the market share given it wants to upgrade the patients with another product.

Related Tags

  • Sun Pharma
sidebar mobile


14 Apr 2024   |   07:25 PM
14 Apr 2024   |   07:23 PM
14 Apr 2024   |   07:21 PM
14 Apr 2024   |   07:15 PM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.


Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp